J A Dormandy

Summary

Country: UK

Publications

  1. ncbi Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11)
    J A Dormandy
    Department of Clinical Vascular Research, Ingelby House, St George s Hospital, Blackshaw Road, London SW17 0QT, UK
    Atherosclerosis 202:272-81. 2009
  2. ncbi Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
    John A Dormandy
    Department of Clinical Vascular Research, Ingelby House, St Georges Hospital, Blackshaw Road, London SW17 0QT, UK
    Lancet 366:1279-89. 2005
  3. ncbi Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive
    John Dormandy
    Department of Clinical Vascular Research, St George s Hospital, London, UK
    Drug Saf 32:187-202. 2009
  4. ncbi A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease
    T M Loosemore
    Department of Vascular Surgery, St George s Hospital, Tooting, London, UK
    Int Angiol 13:133-42. 1994

Detail Information

Publications4

  1. ncbi Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11)
    J A Dormandy
    Department of Clinical Vascular Research, Ingelby House, St George s Hospital, Blackshaw Road, London SW17 0QT, UK
    Atherosclerosis 202:272-81. 2009
    ..The presence of PAD increased the risk of all major cardiovascular events. Those without PAD at baseline seemed to benefit more from pioglitazone treatment than the overall PROactive population...
  2. ncbi Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
    John A Dormandy
    Department of Clinical Vascular Research, Ingelby House, St Georges Hospital, Blackshaw Road, London SW17 0QT, UK
    Lancet 366:1279-89. 2005
    ..Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes...
  3. ncbi Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive
    John Dormandy
    Department of Clinical Vascular Research, St George s Hospital, London, UK
    Drug Saf 32:187-202. 2009
    ..These results suggest that any beneficial effects of pioglitazone on macrovascular outcomes are accompanied by good long-term tolerability in this population of very high-risk patients with type 2 diabetes and established CVD...
  4. ncbi A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease
    T M Loosemore
    Department of Vascular Surgery, St George s Hospital, Tooting, London, UK
    Int Angiol 13:133-42. 1994
    ..Meta-analysis of all other RCTs of pharmacotherapeutic agents in patients with Fontaine Stage III and IV POAD showed no significant benefit over placebo for any of the endpoints reported...